DURECT CORPORATION (DRRX) Stock Price, Forecast & Analysis
NASDAQ:DRRX • US2666055007
DRRX Key Statistics, Chart & Performance
The current stock price of DRRX is 1.91 USD. In the past year, price increased by 26.49%.
DRRX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to DRRX. When comparing the yearly performance of all stocks, DRRX is one of the better performing stocks in the market, outperforming 96.77% of all stocks.
DRRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DRRX. DRRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
DRRX Financial Highlights
Over the last trailing twelve months DRRX reported a non-GAAP Earnings per Share(EPS) of -0.1. The EPS increased by 83.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.86% | ||
| ROE | -99.86% | ||
| Debt/Equity | 0 |
DRRX Forecast & Estimates
7 analysts have analysed DRRX and the average price target is 2.55 USD. This implies a price increase of 33.51% is expected in the next year compared to the current price of 1.91.
For the next year, analysts expect an EPS growth of -105.89% and a revenue growth -92.31% for DRRX
DRRX Ownership
DRRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.34 | 966.197B | ||
| JNJ | JOHNSON & JOHNSON | 21.32 | 586.592B | ||
| MRK | MERCK & CO. INC. | 22.88 | 296.105B | ||
| PFE | PFIZER INC | 9.21 | 154.083B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.25 | 124.384B | ||
| ZTS | ZOETIS INC | 19.09 | 57.184B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.91 | 26.184B | ||
| VTRS | VIATRIS INC | 5.9 | 17.564B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.25 | 13.013B | ||
| AXSM | AXSOME THERAPEUTICS INC | 200.12 | 8.226B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DRRX
Company Profile
DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. The company is headquartered in Cupertino, California and currently employs 13 full-time employees. The company went IPO on 2000-09-28. The firm is engaged in the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in alcoholic hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Therapy designation, and metabolic dysfunction-associated steatohepatitis (MASH) is also being explored. Its commercial pharmaceutical product includes POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology. The company has developed a proprietary drug product for the treatment of ADHD called Methydur.
Company Info
DURECT CORPORATION
10240 Bubb Road
Cupertino CALIFORNIA 95014 US
CEO: James E. Brown
Employees: 21
Phone: 14087771417
DURECT CORPORATION / DRRX FAQ
What does DURECT CORPORATION do?
DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. The company is headquartered in Cupertino, California and currently employs 13 full-time employees. The company went IPO on 2000-09-28. The firm is engaged in the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in alcoholic hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Therapy designation, and metabolic dysfunction-associated steatohepatitis (MASH) is also being explored. Its commercial pharmaceutical product includes POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology. The company has developed a proprietary drug product for the treatment of ADHD called Methydur.
What is the current price of DRRX stock?
The current stock price of DRRX is 1.91 USD. The price decreased by -1.04% in the last trading session.
Does DURECT CORPORATION pay dividends?
DRRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of DRRX stock?
DRRX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the employee count for DRRX stock?
DURECT CORPORATION (DRRX) currently has 21 employees.